Early Cancer Care FAQ

Similar documents
Comprehensive cancer cover

Comprehensive cancer cover

Comprehensive Cancer Cover

Dread Disease Insurance towards local experience

Futura. Cancer cover guide

Protection. Cancer Cover. Helping to protect you financially

Enhancement Date. Summary. For policyholders. aia.com.au. Sub heading

Aviva Group Protection Our guide to cancer

Asteron Lifeguard Changes in Detail

Asteron Lifeguard Changes in Detail

Cancer in Ireland with estimates for

Endometrial adenocarcinoma icd 10 code

Cancer in Estonia 2014

A patient s guide to understanding. Cancer. Screening

Cancer in Ireland : Annual Report of the National Cancer Registry

Cancer in Ireland : Annual Report of the National Cancer Registry

Overview of 2010 Hong Kong Cancer Statistics

Oncology 101. Cancer Basics

CANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

Ovarian Cancer What you need to know

Macmillan Publications

Common Questions about Cancer

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

ANNUAL CANCER REGISTRY REPORT-2005

Cancer Association of South Africa (CANSA)

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

Epidemiology in Texas 2006 Annual Report. Cancer

Types of Hysterectomy for Non-cancerous Conditions: Understanding Your Doctor s Recommendations

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Cancer in Halton. Halton Region Cancer Incidence and Mortality Report

This information explains the advice about suspected cancer that is set out in NICE guideline NG12.

CELLULAR PATHOLOGY TURNAROUND TIMES

Everyone deserves a better Tomorrow.

Personal Data. Present Symptoms

Do you need extra cover for very early stage cancer?

Company/Group Name: Business Telephone: Fax: Option 2:

Overview of 2009 Hong Kong Cancer Statistics

What is endometrial cancer?

Arkansas Health Care Payment Improvement Initiative COPD Algorithm Summary

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Cancer: recent advances and implications for underwriting

Information Services Division NHS National Services Scotland

Cancer , The Patient Education Institute, Inc. ocf80101 Last reviewed: 06/08/2016 1

PATIENT INFORMATION. Name: First Name MI Last Name. Date of Birth: / / Sex: Male / Female / Declined SSN:

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004

Attending Physician Statement- Cancer or Carcinoma in-situ

Cancer in the Northern Territory :

THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

HEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017

WHAT IS CERVICAL CANCER? Presented by Dr. Sylvia Deganus

REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after

Cytology and Surgical Pathology of Gynecologic Neoplasms

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

CASEFINDING. KCR Abstractor s Training

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

Cancer Facts & Figures for African Americans

American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013

MEDICAL DEFINITIONS REFERENCE GUIDES

Clinical Biochemistry Department City Hospital

BCCCP Approved ICD-9 Code List Fiscal Year 2010

COVER WHERE IT MATTERS. Our 17 ABI+ definitions explained. Protection For advisers only

CODING PRIMARY SITE. Nadya Dimitrova

Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute

Endometrial polyp icd-10

Burden of Cancer in California

Top Tier. Medical Breast Specialist, P.C.

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

SUPPLEMENTARY MATERIAL Risk of cancer in patients with thyroid disease and venous thromboembolism

What You Need to Know About Ovarian Cancer

Bowel Cancer Information Leaflet THE DIGESTIVE SYSTEM

Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???

Overview of 2013 Hong Kong Cancer Statistics

Icd 10 code metastatic adenocarcinoma endometrial

-1- Pathology Department (code: 0605) Final Exam for Third year students Date: Time allowed: 2 hours. Paper II (75 marks).

Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER

Terminology in Health Care and Public Health Settings

PATIENT INFORMATION. about CERVICAL CANCER

CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996

Lori Boyce, CHS AVP, Underwriting, Risk Management & Research/Development Manulife Financial

Cancer: Past, Present and Future View from the Korean market

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer

Bioengineering and World Health. Lecture Twelve

CELLULAR PATHOLOGY TURNAROUND TIMES

Female Reproduc.ve System. Kris.ne Kra7s, M.D.

HUNT CANCER INSTITUTE CANCER SERVICES REPORT 2014

Colorectal Cancer Screening

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

Cancer in Women. Lung cancer. Breast cancer

Supplementary Online Content

Outcomes Report: Accountability Measures and Quality Improvements

SUGGESTIVE FINDINGS REVEALED AT AUTOPSY IN PATIENTS TREATED BY RADIATION *

Transcription:

If you need more information, you can call 6722 2293 (Mon-Fri, 9am-5pm), email our Financial Protection Specialists at financial2@ocbc.com or visit any of our OCBC branches. Q1. What is this Early Cancer Care offer? A1: Early Cancer Care is a specially designed Cancer Protection plan offered to selected OCBC customers that covers Early Cancer (including Carcinoma-in-situ) and Major Cancers. This plan is guaranteed renewable on a yearly basis up to the policy anniversary where the customer would be age 85 on his/her next birthday. Customers enjoy level premiums throughout the life of the plan (subject to any adjustments to premium rates based on future claim experience). Q2. What is a level premium? A2: The premium chargeable each year is the rate based on the customer s age at the time of sign-up and there are no yearly increases in premium. The premium rates for this policy are not guaranteed and may be adjusted based on future claim experience. Adjusted rates, if any will be advised prior to policy renewals. Q3. What is the Guaranteed Issue Offer (GIO) about? A3: Early Cancer Care is an exclusive Guaranteed Issue Offer available to selected OCBC customers for a limited time period. Application is fuss-free with no medical underwriting or medical examination. Customers will however need to answer a single health question. Q4. How long will the customer be able to enjoy the cancer coverage for? A4: Early Cancer covers the customer as long as the policy remains inforce, until the policy anniversary on which the customer would be age 85 next birthday. Q5. What is the difference between Early Cancer and Major Cancers? A5: Early Cancer broadly refers to early-stage cancers such as carcinoma-in-situ found in nasopharynx, lungs, breasts, uterus, ovary, fallopian tubes, vulva, vagina, cervix, liver, stomach, colon, bladder, rectum, penis and testis. Major Cancers broadly refers to malignant tumours inclusive of leukaemia, lymphoma, and sarcoma. Exclusions apply; please refer to the standard definitions (version 2014) for severe stage critical illnesses provided by the Life Insurance Association Singapore (LIA) at www.lia.org.sg. Refer to Appendix A for Early Cancer and Major Cancers for more details. Q6. What is the difference between Plans A, B and C? A6: The features and benefits of Plans A, B and C vary in terms of coverage amount. Customers may choose from 3 different amounts of Benefit Amount of S$50,000 (Plan A), S$100,000 (Plan B) and S$150,000 (Plan C), to bridge protection gaps or enhance the customer s existing Critical Illness coverage, as Early Cancer Care will make payment on top of the customer s existing Critical Illness policies. Upon the admission of a claim for Early Cancer or Major Cancers, whichever is the earlier, Cancer Recovery Benefit of S$1,000 (Plan A), S$2,000 (Plan B) and S$3,000 (Plan C) monthly will also be paid in cash for a period of 6 months. Plans A, B and C all have a Premium Waiver Benefit. Q7. What is the claimable amount if diagnosed with Early Cancer or Major Cancers? A7: Upon diagnosis of Early Cancer for the first time, 40% of the Benefit Amount will be payable to the customer. Early Cancer Benefit is only claimable once. If the customer is diagnosed with Major Cancers for the first time, the full amount of the Benefit Amount less any amounts previously paid out for Early Cancer (if any), will be paid, and the policy will terminate. In addition, the plan will pay out the Cancer Recovery Benefit upon the diagnosis of the Early Cancer or Major Cancers, whichever is the earlier. The Cancer Recovery Benefit may only be claimed once. ECC_FAQ_version1.0_(12/09/2017) Page 1 of 5

Benefit Level (% of Benefit Amount) Stage Plan A Plan B Plan C (BA = $50,000) (BA = $100,000) (BA = $150,000) Claim @ Early Cancer 40% 40% 40% Claim @ Major Cancers 100% 100% 100% Q8. What would happen to the remaining 60% of the benefit amount if the customer had been diagnosed with Early Cancer but recovers from it? A8: Great Eastern will pay the remaining 60% of the benefit amount upon a diagnosis of Major Cancers. Q9. What is Cancer Recovery Benefit? A9: Cancer Recovery Benefit is a monthly cash payout over 6 months upon diagnosis of Early Cancer or Major Cancers, whichever is earlier. The Cancer Recovery Benefit may only be claimed once. In the event of the customer s death during the Cancer Recovery Benefit payout period, a lump sum payout of the remaining Cancer Recovery Benefit will be made. Plan A Plan B Plan C Cancer Recovery Benefit (monthly payout for 6 months) $1,000 $2,000 $3,000 Q10. Would the customer s future premiums be waived upon a cancer claim being made? A10: Yes, upon diagnosis of Early Cancer, the Premium Waiver Benefit will waive the customer s future premiums until the policy terminates. In the event of a claim for Major Cancers, the customer does not need to pay premiums while receiving the Cancer Recovery Benefit (if applicable). Q11. What are the available avenues for customers to apply? A11: This is an exclusive offer to selected OCBC customers only. To apply, the customer can simply logon his/her OCBC internet banking via the designated URL or complete an Early Cancer Care application form available at all OCBC branches. Q12. Customer is unsure if he/she will be covered for certain pre-existing or existing conditions. A12: To be eligible for the offer, the customer has to answer a health question to declare he/she has never been diagnosed with a Cancer/ Carcinoma-in-situ/ Leukaemia/ Lymphoma, and has not been investigated nor awaiting any medical consultation or follow-up for any of the medical conditions stated in the question. Refer to Appendix B for the Help Text. The plan does not cover pre-existing cancer. Q13. Can the customer sign up for his/her spouse or children? A13: No, this is an exclusive offer to selected OCBC customers only. Selected customers will receive a SMS, Electronic Direct Mailer and/or Direct Mailer of this exclusive offer. Q14. Can the customer upgrade/downgrade his/her Early Cancer Plan in the future? A14: Upgrading of plan is not allowed after purchase. However, the customer may request for a downgrade in writing, subject to Great Eastern s discretion. Any downgrade will only be effective at the next premium due date following approval. Q15. How does Early Cancer Care complement the customer s existing hospital plan and/or critical illness plan? A15: Early Cancer Care covers the customer from Early Cancer (including Carcinoma-in-situ) and Major Cancers. Upon diagnosis of Early Cancer or Major Cancers, the customer will receive a lump sum cash benefit plus 6 months of Cancer Recovery Benefit. This gives the customer higher coverage to deal with the burden of ECC_FAQ_version1.0_(12/09/2017) Page 2 of 5

treatment or recovery costs. Future premiums will be waived throughout the policy term in the event of an Early Cancer claim. Q16. How do customers make a claim? A16: To make a claim, please visit Great Eastern s customer service lobby. Customer Service Operating Hours: Mondays to Fridays, 9.00am to 5.30pm. Closed on Saturdays, Sundays and Public Holidays. Or call 1800 248 2888. Q17. Do customers get immediate cover? A17: There is a 90-day waiting period from the date of issue of the policy. The customer will not be entitled to the benefits for a diagnosis of cancer within 90 (ninety) days from the date of issue of the policy. Q18. What are the exclusions to this plan? A18: Pre-existing cancer is not covered. Any cancer caused directly or indirectly by Acquired Immunodeficiency Syndrome (AIDS) or infection by any Human Immunodeficiency Virus (HIV); or caused directly or indirectly by alcohol or drug abuse is also not covered. The customer will not be entitled to the benefits for a diagnosis of cancer within 90 (ninety) days from the date of issue of the policy and where the policy was reinstated, 90 (ninety) days from the date of reinstatement of the policy. Q19. Can customer purchase more than 1 plan? A19: No, each customer may only purchase 1 plan. ECC_FAQ_version1.0_(12/09/2017) Page 3 of 5

APPENDIX A Definition of Early Cancer and Major Cancers: Early Cancer Refer to any one of the following minor cancer conditions: 1. Carcinoma-in-situ of the following sites: Breast, uterus, ovary, fallopian tube, vulva, vagina, cervix uteri, colon, rectum, penis, testis, lung, liver, bladder, stomach or nasopharynx. The diagnosis of Carcinoma-in-situ must be positively established by microscopic examination of fixed tissues. Clinical diagnosis or the Cervical Intraepithelial Neoplasia (CIN) classification which reports CIN I, CIN II, CIN III (severe dysplasia without carcinoma-in-situ) does not meet with the required definition and are specifically excluded. Carcinoma-in-situ of the skin or biliary system are also specifically excluded. 2. Prostate Cancer that is histologically described using the TNM Classification as T1N0M0 or Prostate cancers described using another equivalent classification. 3. Thyroid Cancer that is histologically described utilising TNM Classification as T1N0M0 as well as Papillary micro-carcinoma of Thyroid that is less than 1cm in diameter. 4. Urinary Bladder Cancer that is histologically described utilising the TNM Classification as T1N0M0 (including Papillary micro-carcinoma of Bladder). Major Cancers Refer to a malignant tumour positively diagnosed with histological confirmation and characterized by the uncontrolled growth of malignant cells with invasion and destruction of normal tissue. The term malignant tumour includes leukemia, lymphoma and sarcoma. For the above definition, the following are excluded: All tumours which are histologically classified as any of the following: Pre-malignant; Non-invasive; Carcinoma-in-situ; Having borderline malignancy; Having any degree of malignant potential; Having suspicious malignancy; Neoplasm of uncertain or unknown behavior; or Cervical Dysplasia CIN-1, CIN-2 and CIN-3; Any non-melanoma skin carcinoma unless there is evidence of metastases to lymph nodes or beyond; Malignant melanoma that has not caused invasion beyond the epidermis; All Prostate cancers histologically described as T1N0M0 (TNM Classification) or below; or Prostate cancers of another equivalent or lesser classification; All Thyroid cancers histologically classified as T1N0M0 (TNM Classification) or below; All tumours of the Urinary Bladder histologically classified as T1N0M0 (TNM Classification) or below; All Gastro-Intestinal Stromal tumours histologically classified as T1N0M0 (TNM Classification) or below and with mitotic count of less than or equal to 5/50 HPFs; Chronic Lymphocytic Leukaemia less than RAI Stage 3; and All tumours in the presence of HIV infection. ECC_FAQ_version1.0_(12/09/2017) Page 4 of 5

APPENDIX B Health Declaration/Question Help Text Stated Conditions Colorectal polyp Liver disease Persistent coughing of blood Diarrhoea lasting more than one week Unexplained weight loss of more than 5 kg Abnormal breast lump Tumour or lump Ovarian / Uterine growth Abnormal tumour markers Unusual bleeding or discharge Help Text You will not be required to declare colon polyp which was removed, confirmed to be benign and do not require regular monitoring or follow up on the doctor s advice. This includes any type of hepatitis (except Hepatitis A), liver enlargement, liver cirrhosis, end-stage liver disease or fatty liver requiring regular monitoring or follow up This includes coughing of blood or bloody sputum lasting more than a day You will not be required to declare diarrhea which was caused by stomach infection or food poisoning. You will not be required to declare intentional or planned weight loss due to dietmanagement or exercise. You will not be required to declare any fully investigated breast cyst or lump which was removed, confirmed to be benign and do not require regular monitoring or follow-up on the doctor s advice. This includes any cyst, nodules, polyp or tumour. You will not be required to declare any fully investigated tumour or lump which was removed, confirmed to be benign and do not require regular monitoring or followup on the doctor s advice. You will not be required to declare uterine fibroid and endometriosis that were benign and do not require regular monitoring or follow-up on the doctor s advice Tumor markers include but not limited to CA 19-9, CA 15-3, CA 125, CEA, AFP, PSA etc. You will not be required to declare incidental elevation of tumor markers which were fully investigated, confirmed to be non-precancerous or non-cancerous and do not require any follow-up on the doctor s advice You will not be required to declare menstrual disorder or discharge from nipples which were fully investigated, confirmed to be non-precancerous or non-cancerous and do not require regular monitoring or follow-up on the doctor s advice ECC_FAQ_version1.0_(12/09/2017) Page 5 of 5